The Baird/STR Hotel Stock Index was up 0.2% for the same period ... The deal also gave the company a 28% stake in Accor Luxury and upscale hotel business in …
UBS analysts, who raised their price target on Accor's stock to 36.50 euros from 29.10 euros, say they have increased their RevPar growth forecast to 3.0 percent from 2.0 percent for 2014 and to 3.0 percent from 1.3 percent for 2015. The …
In an amended 13D filing on Acorda Therapeutics (Nasdaq: ACOR), Daniel Loeb's Third Point LLC disclosed they lowered their stake in the company to 4.1% (1 million shares), down from 9.9%. In his original 13D filing, Loeb requested that …
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update ... dependent on changes in the market price of our common stock, (ii) non-cash interest charges related to the …
Acorda Therapeutics Inc. (ACOR) announced Tuesday morning that it has received ... this morning and is now down 6.88 at $18.83 with volume at over a 2-month high. The stock has dropped to a 2-month low.
StockMarketWire.com - Action Hotels founder and chairman Sheikh Mubarak A M Al-Sabah met with Accor's chairman and chief executive Sebastien Bazin in London yesterday to discuss their growing partnership in the Middle East and …
One stock that might be an intriguing choice for investors right now is Acorda Therapeutics, Inc. (ACOR). This is because this security in the Medical – Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is in …
with Accor rumoured to be in exclusive due diligence to purchase the hotel group. But this morning Mantra released a statement to the stock exchange regarding “recent press speculation”, confirming the rumours. It stated, “Mantra …
Accor shares were up 4.5 percent to 25.70 euros at 0933 GMT, the top gainer on the French blue-chip CAC 40 index and giving it a market value of about 5.9 billion euros. The stock is up a third in value this year. The sale includes Accor’s …